11 assets in Clear Cell Sarcoma

Therapeutic assets addressing Clear Cell Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Clear Cell Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Cabozantinib Clear Cell Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Zoledronate Clear Cell Sarcoma	University of Florida	P1/2	CCC (48)
Cyclophosphamide Clear Cell Sarcoma	St. Jude Children's Research Hospital	P1	CC (47)
b7-h3 car t cells Clear Cell Sarcoma	St. Jude Children's Research Hospital	P1	CC (43)
Fludarabine Clear Cell Sarcoma	St. Jude Children's Research Hospital	P1	CC (43)
Mesna Clear Cell Sarcoma	St. Jude Children's Research Hospital	P1	CC (43)
Pembrolizumab Clear Cell Sarcoma	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr Clear Cell Sarcoma	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt Clear Cell Sarcoma	Seattle Children's Hospital	P1	CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg Clear Cell Sarcoma	Seattle Children's Hospital	P1	CC (43)